英语翻译The biotech company Alnylam announced in June that its d

The biotech company Alnylam announced in June that its drug ALN-VSP cut off blood flow to 62 percent of liver-cancer tumors in those 19 patients, by triggering a rarely used defense mechanism in the body to silence cancerous genes。生物科技公司Alnylam六月宣布,其药品ALN-VSP 在该十九个病人中切断了达到62%的肝癌肿瘤的血液流,而这是通过触动一个很少被用到的身体防护机能,从而达到抑制癌变基因（的效果）。Whereas conventional drugs stop disease-causing proteins, ALN-VSP uses RNA interference (RNAi) therapy to stop cells from making proteins in the first place, a tactic that could work for just about any disease。当传统的药品抑制产生疾病的蛋白质时,ALN-VSP 则首先（或在源头上）利用RNA 干扰(RNAi) 疗法来抑制制造蛋白质的细胞,这种方法（理论上）可以来对付任何疾病。 （PS,RNA可以翻译做核糖核酸）“Imagine that your kitchen floods,” says biochemist and Alnylam CEO John Maraganore。 “Today’s medicines mop it up。 RNAi technology turns off the faucet。”Alnylam （公司）的CEO同时也是生化学家的John Maraganore（约翰 马拉噶诺尔）说：“想象一下你的厨房（因没关水龙头）被水淹了,今天的药品只是用拖把把水拖掉,而RNAi 技术则是关掉水龙头。”以上,仅供参考